July 26, 2011 / 12:32 IST
Glenmark Pharma is expected to report a rise of 13.7% in its first quarter FY12 profit after tax to Rs 177 crore against Rs 155 crore in same quarter the previous year.
This is the first quarter that the company will be reporting numbers in IFRS. Hence, YoY comparison is difficult as corresponding quarters' numbers were not in IFRS. According to the company there is a variance of 3-4% on the topline due to the change.
Revenues are seen going up 15.4% to Rs 803 crore from Rs 696.3 crore year-on-year.
Howeer, EBITDA is likely to go down 6% (YoY) to Rs 220 crore from Rs 234 crore. Company is expected to post decline in operating profit margin to 27.4% versus 33.6% (which includes licensing income).
Watch out for: -Numbers to be boosted by USD 25 million from Sanofi on licensing agreement on GRB 500
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
